{"id":"NCT02448381","sponsor":"Soligenix","briefTitle":"FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)","officialTitle":"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12","primaryCompletion":"2020-06","completion":"2020-11","firstPosted":"2015-05-19","resultsPosted":"2022-04-15","lastUpdate":"2022-04-15"},"enrollment":169,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cutaneous T-Cell Lymphoma"],"interventions":[{"type":"DRUG","name":"SGX301 (synthetic hypericin)","otherNames":["Hypericin","Synthetic Hypericin"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"SGX301","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the use of SGX301, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).","primaryOutcome":{"measure":"Number of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Defined as a â‰¥50% Improvement in the Composite Assessment of Index Lesion Disease Severity (CAILS) Score When Compared to Patients Receiving Placebo","timeFrame":"8 weeks","effectByArm":[{"arm":"SGX301","deltaMin":19,"sd":null},{"arm":"Placebo","deltaMin":2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.04"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":33,"countries":["United States"]},"refs":{"pmids":["35857290","32632956"],"seeAlso":["https://www.rarediseases.org/","http://www.clfoundation.org/"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":116},"commonTop":["Application site pain","Respiratory, thoracic and mediastinal disorders","Injury, poisoning and procedural complications","Upper respiratory tract infection","Pruritus"]}}